Breast Cancer Modifies the Lymphatic Vessels Through Which It Travels to Lymph Nodes, From Where It Can Spread Elsewhere in the Body. The Cancer Cells Use the Matrix Gla Protein to Bind to Lymphatic Vessels. The Discovery Enables Developing Targeted Therapies That Prevent This Process. 🩺💖🦠💉

Read Full Article

#BreastCancer #LymphaticSystem #CancerResearch #TargetedTherapies #HealthInnovation

Breast cancer hijacks the immune system’s alarm by rewiring the cGAS-STING pathway, transforming anti-tumor defense into chronic inflammation that fuels tumor growth, suppresses immunity, increases PD-L1 expression, and reveals a clear, targetable vulnerability to immunotherapy. 🩺💔🦠✨

Read Full Article

#BreastCancer #ImmuneSystem #cGASSTING #Immunotherapy #ChronicInflammation

Clinical Trial: Cannabis Topicals 🌿 Mitigate Pain, 💊 Improve Physical Functioning in Breast Cancer Patients 🎗️

Read Full Article

#ClinicalTrial #CannabisTopicals #BreastCancer #PainManagement #HealthInnovation

✅ Breast cancer patients using topical balms with plant-derived cannabinoids reported reduced musculoskeletal pain after taking aromatase inhibitors, according to clinical trial data from the University of Minnesota.

✅ The study involved 21 patients randomly assigned to apply either CBD-dominant or THC-dominant balms three times daily for at least two weeks.

✅ Eighty-six percent of participants saw improvements in their pain scores, with THC-dominant balms showing the greatest relief. Benefits lasted up to four weeks.

✅ The cannabis balms were well-tolerated, did not affect estradiol levels, and showed no systemic THC absorption, suggesting they are safe for AIMSS patients.

#MedicalCannabis #BreastCancer #PainRelief

🧬 A simple DNA blood test could predict which breast cancer treatment will work best, 🫀 even before therapy begins. 💡 This liquid biopsy may help doctors tailor care, avoid ineffective treatments, and improve outcomes for the world’s most common cancer. 🩺

Read Full Article

#LiquidBiopsy #BreastCancer #PersonalizedTherapy #TailoredTreatment #HealthInnovation

🔬 New Blood Test Predicts Breast Cancer Treatment Response
A simple DNA blood test developed by researchers at the Institute of Cancer Research, London (ICR) can predict how well breast cancer patients will respond to treatment, potentially allowing for faster, more personalized care and avoiding ineffective therapies.

🔬 How it Works & Early Results
The test analyzes circulating tumor DNA (ctDNA) released by cancer cells into the blood. In a study of 167 patients with advanced breast cancer, low ctDNA levels at the start of treatment were strongly associated with a better response. For one group, low ctDNA was linked to 10.2 months of progression-free survival versus 4.4 months with higher levels.

🔬 Four-Week Check-in Shows Promise
A follow-up analysis after just one treatment cycle also showed strong links between ctDNA levels and patient outcomes. Patients with undetectable ctDNA after four weeks saw their cancer kept at bay for significantly longer periods compared to those with detectable levels.

#BreastCancer #MedicalResearch #CancerTreatment

Scientists 🔬 develop ✨ new 🧪 nanomaterial 🧬 that triggers ⚗️ chemical reactions 💥 inside cancer cells, killing 💀 them 🧬 while leaving healthy tissues ❤️ alone. When administered in mice 🐭 bearing human breast cancer cells 🧬, it completely eradicated the cancer 🎯 without side effects ⚠️, with long-term prevention of recurrence 🔁.

Read Full Article

#CancerResearch #Nanomedicine #PreclinicalStudy #BreastCancer #MedicalInnovation

📊 Over a quarter of healthy years lost to breast cancer are due to lifestyle factors like red meat intake and smoking, according to the largest study of its kind, published in The Lancet Oncology.

📈 Global breast cancer cases in women are projected to rise by a third by 2050, from 2.3 million in 2023 to over 3.5 million.

🥗 A healthy lifestyle, including not smoking, sufficient physical activity, lower red meat consumption, and a healthy BMI, could prevent over a quarter of healthy years lost due to breast cancer worldwide.

#BreastCancer #Health #Oncology

Researchers map rogue breast cancer cells that divide remarkably slowly and can evade detection for decades, helping explain how breast cancer can return years after successful treatment

Read Full Article

#BreastCancer #CancerResearch #DormantCells

🔬 Researchers have identified how some breast cancer cells survive therapy by dividing extremely slowly, not by becoming dormant. This "stealthy" pathway allows them to evade detection for years and cause late relapses, particularly in estrogen receptor-positive (ER+) breast cancer.

🔬 Published in Nature Communications, the study by Garvan Institute of Medical Research and UNSW Sydney highlights that these slow-growing cells, once detected or disruptive, can become life-threatening and resistant to chemotherapy.

🔬 The research pinpointed the Rac1 pathway as a key driver of these slow-growing, evasive cancer cells. Blocking this pathway with experimental inhibitors showed promise in shrinking tumors in lab models.

🔬 Findings could lead to new approaches to prevent metastasis and recurrence, offering hope for patients facing the threat of late breast cancer relapse.

#BreastCancer #CancerResearch #MedicalBreakthrough

Groundbreaking genomic test could spare millions of breast cancer patients chemotherapy | Breast cancer

Read Full Article

#BreastCancer #GenomicTesting #ChemotherapyBreakthrough

🔬 Millions of women with breast cancer may be able to avoid chemotherapy thanks to a new genomic test. The Optima trial, involving over 4,000 patients, found that those with a low score on the Prosigna test could safely be treated with hormone therapy alone, sparing them harsh side effects.

🔬 The Prosigna test analyzes 50 genes in tumor tissue to assess the risk of breast cancer returning within 10 years, allowing doctors to tailor treatment decisions. In the trial, 94% of low-score patients who skipped chemotherapy were recurrence-free after five years, compared to 95% of those who received it.

🔬 These findings, presented at the American Society of Clinical Oncology's annual meeting, could transform healthcare guidelines by enabling more personalized medicine and reducing unnecessary toxicity for patients.

#BreastCancer #GenomicTesting #PersonalizedMedicine

✅ The OPTIMA trial, involving over 4,400 patients, shows a gene test called Prosigna can identify early-stage breast cancer patients who can safely skip chemotherapy without worsening outcomes.

✅ In the trial, 68% of patients with a low Prosigna score avoided chemotherapy, with 93.6% remaining alive and cancer-free after five years, similar to those who received it.

✅ This breakthrough could lead to wider NHS use of Prosigna testing, sparing many patients the distress and side effects of unnecessary chemotherapy, and is expected to inform NICE guidance.

#BreastCancer #ClinicalTrial #Oncology

🔬 Large study suggests GLP-1 drugs may lower breast cancer risk: A Penn Medicine analysis of over 110,000 women (ages 45-80) found GLP-1 users were about 30% less likely to develop breast cancer.

📅 Findings presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and published in JCO Oncology Practice today.

🔬 Researchers are planning a multi-site clinical trial to further investigate this potential link, as current evidence is observational.

#GLP1 #BreastCancer #MedicalResearch

UC Berkeley, UCSF AI model reduces screening time for breast cancer in high-risk patients

Read Full Article

#BreastCancer #AIMedicine #EarlyDetection

📊 UC Berkeley and UCSF researchers developed an AI model, Mirai, to identify high-risk breast cancer patients for faster mammogram interpretations and diagnoses.

⏰ At Zuckerberg San Francisco General Hospital, the AI model helped reduce average wait times for diagnostic evaluations from weeks to about an hour.

💡 The AI flagged 12.7% of screened patients, close to the target of 10%, with the potential to personalize screening and surveillance based on individual risk.

#AIinHealthcare #BreastCancer #MedTech

Study Finds Chemotherapy-Free Treatment Shows Promise for Some Patients With Metastatic Breast Cancer. In the trial, 97% of patients experienced clinical benefit during the first 6 months of treatment. After a median follow-up of approximately 39 months, nearly 93% of participants were still alive.

Read Full Article

#BreastCancer #ChemotherapyFree #MetastaticBreastCancer

✨ Chemo-Free Breast Cancer Treatment Shows Promise: A Phase 1/2 clinical trial found a combination of four targeted therapies effective for HR-positive, HER2-positive metastatic breast cancer patients, potentially offering an alternative to chemotherapy.

📈 High Patient Benefit: In the ASPIRE trial, 97% of patients experienced clinical benefit within six months, with a median progression-free survival of nearly 25 months. Nearly 93% were still alive after about 39 months of follow-up.

💊 Manageable Side Effects: The treatment's side effects were generally expected, including low white blood cell counts and diarrhea. Only one patient stopped treatment due to side effects, with no treatment-related deaths reported.

#BreastCancer #TargetedTherapy #Oncology

💡 Higher BMI in early adulthood (age 20) linked to lower post-menopausal breast cancer risk, with breast density playing a key role.

🔬 Researchers analyzed data from 33,816 women over a decade, finding a 15% drop in post-menopausal breast cancer risk for every 5-point BMI increase at age 20.

📊 Lower breast density may account for nearly 60% of the risk reduction associated with higher early-adulthood BMI.

🤔 The findings suggest early life exposures can have lasting health impacts, but maintaining a healthy weight later in life remains crucial.

#BreastCancer #HealthResearch #WomenHealth

📈 Premenopausal Breast Cancer Burden Rising Globally

🌏 High-income countries lead in premenopausal breast cancer incidence (51.5 per 100,000 population), while lower-income nations face higher mortality and disability rates. The disease burden is projected to increase through 2039, except in high-income regions.

🥩 Diet high in red meat is the leading risk factor for attributable burden (11.2%), with increasing mortality and disability linked to its consumption, particularly in low-to-middle income countries.

📊 Incidence has been rising globally since 1990, with the fastest increase seen in medium Sociodemographic Index (SDI) countries. Mortality and disability rates have also increased overall, with the highest rise in medium-to-low SDI nations.

📈 Projections until 2039 indicate a continued increase in mortality and disability from premenopausal breast cancer. While risks from smoking and alcohol are expected to decrease, those from secondhand smoke and high red meat consumption are projected to rise.

#BreastCancer #WomensHealth #HealthResearch